Brivanib Alaninate – 50 mg

Brand:
Cayman
CAS:
649735-63-7
Storage:
-20
UN-No:
Non-Hazardous - /

Brivanib alaninate is the L-alanine prodrug form of brivanib (Item No. 23690), a VEGF receptor 2 (VEGFR2) and FGF receptor 1 (FGFR1) inhibitor.{36328,47106} Brivanib alaninate (3 mg/kg per day) reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis.{47107} It reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition when administered at a dose of 107 mg/kg.{47106}  

 

Available on backorder

SKU: 26081 - 50 mg Category:

Description

A prodrug form of brivanib; reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis at 3 mg/kg per day; reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition at 107 mg/kg


Formal name: L-alanine, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester

Synonyms:  BMS 582664

Molecular weight: 441.5

CAS: 649735-63-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|FGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Toxicology|Drug Metabolism